Evaluation of a new hydrophobic acrylic intraocular lens in the rabbit model

Session Details

Session Title: New IOLs: Material & Preload IOL

Session Date/Time: Monday 24/09/2018 | 08:00-10:30

Paper Time: 09:45

Venue: Room A3, Podium 2

First Author: : L.Werner USA

Co Author(s): :    N. Ellis   J. Heczko   M. Ong   R. Jain   P. Wolfe   N. Mamalis     

Abstract Details

Purpose:

To evaluate a new hydrophobic acrylic intraocular lens (IOL) in vivo in the rabbit model, and compare it with a commercially available lens.

Setting:

John A Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.

Methods:

15 New Zealand rabbits received the Clareon CNA0T0 IOL in one eye, and an AcrySof SN60WF in the other. They were followed up with weekly slit lamp examinations, evaluating uveal and capsular biocompatibility, as well as the presence of striae and surface haze. Anterior chamber depth was measured 1 and 4 weeks post-implantation (high-frequency ultrasound). After 4 weeks, the rabbits were sacrificed and the eyes enucleated. The anterior segment was evaluated from the posterior or Miyake-Apple view, and was then processed for complete histopathology.

Results:

There were no statistically significant differences between test (Clareon CNA0T0) and control (AcrySof SN60WF) eyes in terms of postoperative inflammation and capsular biocompatibility, including PCO (P=0.34, paired t test), and ACO (P=0.53, paired t test), as observed during clinical and pathological evaluation. All control lenses had mild or moderate haze, while no test lens exhibited haze (P = 0, Fisher Exact Test). In vivo axial displacement for the test lens was comparable to the control lens and stable over time (P=0.16 and 0.558 respectively, 2-Way RM ANOVA).

Conclusions:

Clareon CNA0T0 IOL is manufactured from a new hydrophobic acrylic material incorporating ultraviolet blocker and blue light filter. Its design is based on the AcrySof SN60WF platform. In this in vivo study, the new IOL showed absence of surface haze while maintaining the biocompatibility and stability of its predecessor.

Financial Disclosure:

... is employed by a for-profit company with an interest in the subject of the presentation